Swiss National Bank lifted its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 9.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,500 shares of the biopharmaceutical company’s stock after purchasing an additional 6,100 shares during the quarter. Swiss National Bank owned about 0.16% of Vanda Pharmaceuticals worth $1,133,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc boosted its holdings in Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,022 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $196,000. American International Group Inc. boosted its holdings in Vanda Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,491 shares during the period. Trexquant Investment LP purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $384,000. Finally, Rice Hall James & Associates LLC boosted its holdings in Vanda Pharmaceuticals by 1.0% during the 2nd quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock valued at $455,000 after acquiring an additional 279 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.

VNDA has been the subject of a number of research analyst reports. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Jefferies Group LLC restated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and an average target price of $21.29.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 16.25 on Friday. The stock’s market cap is $728.94 million. Vanda Pharmaceuticals Inc. has a 52 week low of $12.70 and a 52 week high of $18.99. The stock has a 50 day moving average price of $17.51 and a 200 day moving average price of $15.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. During the same quarter in the prior year, the business earned $0.01 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post ($0.43) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Shares Bought by Swiss National Bank” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/15/vanda-pharmaceuticals-inc-vnda-shares-bought-by-swiss-national-bank.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.